Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas.

ErbB-2 and EGFR (epidermal growth factor receptor) are expressed in lung adenocarcinomas and associated with a poor prognosis. Immunocytochemical analysis revealed erbB-2 and EGFR coexperession as a characteristic feature of most lung adenocarcinomas, and at levels of receptor expression present in...

Full description

Bibliographic Details
Main Authors:	Rachwal, W. J., Bongiorno, P. F., Orringer, M. B., Whyte, R. I., Ethier, S. P., Beer, D. G.
Format:	Online
Language:	English
Published:	1995
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034126/

id	pubmed-2034126
recordtype	oai_dc
spelling	pubmed-20341262009-09-10 Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Rachwal, W. J. Bongiorno, P. F. Orringer, M. B. Whyte, R. I. Ethier, S. P. Beer, D. G. Research Article ErbB-2 and EGFR (epidermal growth factor receptor) are expressed in lung adenocarcinomas and associated with a poor prognosis. Immunocytochemical analysis revealed erbB-2 and EGFR coexperession as a characteristic feature of most lung adenocarcinomas, and at levels of receptor expression present in bronchial epithelial cells. In primary lung tumours and cell lines, erbB-2 detected using Western blot analysis demonstrated low-level phosphotyrosine staining of the 185 kDa band, as compared with breast cancer cell lines. A549 and A427 lung adenocarcinoma cells treated with neu differentiation factor (NDF) showed increased erbB-2 phosphotyrosine staining, but to a much lesser extent than breast cancer cells. The lung cells were examined for expression of the potential autocrine growth factors NDF and transforming growth factor alpha (TGF-alpha) by Northern blot analysis. Both NDF and TFG-alpha mRNA were abundantly expressed in the A549 cells. NDF mRNA was highest during active cell proliferation and decreased in confluent cells or after treatment with the growth-inhibitory steroid dexamethasone. Primary tumours and cell lines expressed EGFR, showing higher basal level phosphotyrosine staining than erbB-2. Treatment with NDF and EGF (epidermal growth factor) stimulated cell growth, and in A549 cells the presence of both factors provided an additive increase in cell growth. The growth stimulus that ligand-activated erbB-2 and EGFR provides to lung adenocarcinoma cells may establish a background of continued cell proliferation over which other critical transforming events may occur. 1995-07 /pmc/articles/PMC2034126/ /pubmed/7599067 Text en
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Rachwal, W. J. Bongiorno, P. F. Orringer, M. B. Whyte, R. I. Ethier, S. P. Beer, D. G.
spellingShingle	Rachwal, W. J. Bongiorno, P. F. Orringer, M. B. Whyte, R. I. Ethier, S. P. Beer, D. G. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas.
author_facet	Rachwal, W. J. Bongiorno, P. F. Orringer, M. B. Whyte, R. I. Ethier, S. P. Beer, D. G.
author_sort	Rachwal, W. J.
title	Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas.
title_short	Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas.
title_full	Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas.
title_fullStr	Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas.
title_full_unstemmed	Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas.
title_sort	expression and activation of erbb-2 and epidermal growth factor receptor in lung adenocarcinomas.
description	ErbB-2 and EGFR (epidermal growth factor receptor) are expressed in lung adenocarcinomas and associated with a poor prognosis. Immunocytochemical analysis revealed erbB-2 and EGFR coexperession as a characteristic feature of most lung adenocarcinomas, and at levels of receptor expression present in bronchial epithelial cells. In primary lung tumours and cell lines, erbB-2 detected using Western blot analysis demonstrated low-level phosphotyrosine staining of the 185 kDa band, as compared with breast cancer cell lines. A549 and A427 lung adenocarcinoma cells treated with neu differentiation factor (NDF) showed increased erbB-2 phosphotyrosine staining, but to a much lesser extent than breast cancer cells. The lung cells were examined for expression of the potential autocrine growth factors NDF and transforming growth factor alpha (TGF-alpha) by Northern blot analysis. Both NDF and TFG-alpha mRNA were abundantly expressed in the A549 cells. NDF mRNA was highest during active cell proliferation and decreased in confluent cells or after treatment with the growth-inhibitory steroid dexamethasone. Primary tumours and cell lines expressed EGFR, showing higher basal level phosphotyrosine staining than erbB-2. Treatment with NDF and EGF (epidermal growth factor) stimulated cell growth, and in A549 cells the presence of both factors provided an additive increase in cell growth. The growth stimulus that ligand-activated erbB-2 and EGFR provides to lung adenocarcinoma cells may establish a background of continued cell proliferation over which other critical transforming events may occur.
publishDate	1995
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034126/
_version_	1611405257486630912

Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas.

Similar Items